Cargando…

Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer

Bevacizumab combined with cytotoxic chemotherapy is the backbone of metastatic colorectal cancer (mCRC) therapy; however, its treatment efficacy is hampered by therapeutic resistance. Therefore, understanding the mechanisms underlying bevacizumab resistance is crucial to increasing the therapeutic e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makondi, Precious Takondwa, Lee, Chia-Hwa, Huang, Chien-Yu, Chu, Chi-Ming, Chang, Yu-Jia, Wei, Po-Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771567/ https://www.ncbi.nlm.nih.gov/pubmed/29342159 http://dx.doi.org/10.1371/journal.pone.0189582

Ejemplares similares

Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer
por: Makondi, Precious Takondwa, et al.
Publicado: (2017)

Development of novel predictive miRNA/target gene pathways for colorectal cancer distance metastasis to the liver using a bioinformatic approach
por: Makondi, Precious Takondwa, et al.
Publicado: (2019)

Identification of Moesin (MSN) as a Potential Therapeutic Target for Colorectal Cancer via the β-Catenin-RUNX2 Axis
por: Huang, Chien-Yu, et al.
Publicado: (2023)

Bromelain inhibits the ability of colorectal cancer cells to proliferate via activation of ROS production and autophagy
por: Chang, Tung-Cheng, et al.
Publicado: (2019)

Novel heavily fucosylated glycans as a promising therapeutic target in colorectal cancer
por: Tsai, Kuei-Yen, et al.
Publicado: (2023)

Cytotoxic properties of unfractionated and fractionated bromelain alone or in combination with chemotherapeutic agents in colorectal cancer cells
por: Tsai, Kuei-Yen, et al.
Publicado: (2023)

Glucose-Regulated Protein 94 Modulates the Response of Osteosarcoma to Chemotherapy
por: Huang, Chien-Yu, et al.
Publicado: (2019)

Human α-defensin 6 (HD6) suppresses CRC proliferation and metastasis through abolished EGF/EGFR signaling pathway
por: Wei, Po-Li, et al.
Publicado: (2022)

PCTAIRE Protein Kinase 1 (PCTK1) Suppresses Proliferation, Stemness, and Chemoresistance in Colorectal Cancer through the BMPR1B-Smad1/5/8 Signaling Pathway
por: Wei, Po-Li, et al.
Publicado: (2023)

2,3,5,4′-Tetrahydroxystilbene (TG1), a Novel Compound Derived from 2,3,5,4′-Tetrahydroxystilbene-2-O-β-D-glucoside (THSG), Inhibits Colorectal Cancer Progression by Inducing Ferroptosis, Apoptosis, and Autophagy
por: Tsai, Kuei-Yen, et al.
Publicado: (2023)

Combination of Two Targeted Medications (Bevacizumab Plus Cetuximab) Improve the Therapeutic Response of Pancreatic Carcinoma
por: Tai, Cheng-Jeng, et al.
Publicado: (2016)

Targeted therapies in the management of colorectal carcinoma: role of bevacizumab
por: Puthillath, Ajithkumar, et al.
Publicado: (2009)

PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients
por: Hsu, Hung-Chih, et al.
Publicado: (2018)

TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
por: Liu, Cheng-Jiang, et al.
Publicado: (2021)

Comparative Effectiveness of Bevacizumab versus Cetuximab in Metastatic Colorectal Cancer Patients without Primary Tumor Resection
por: Su, Yi-Chia, et al.
Publicado: (2022)

Glucose-Regulated Protein 94 Mediates the Proliferation and Metastasis through the Regulation of ETV1 and MAPK Pathway in Colorectal Cancer
por: Batzorig, Uyanga, et al.
Publicado: (2021)

The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis
por: Dai, Jiali, et al.
Publicado: (2019)

Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment
por: Chang, Yu-Shan, et al.
Publicado: (2019)

Effect of electroacupuncture on restless legs syndrome (RLS) in hemodialysis patients: A protocol for systematic review and meta-analysis
por: Chen, Jia-Ming, et al.
Publicado: (2020)

Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer
por: Hsu, Hung‐Chih, et al.
Publicado: (2019)

Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment
por: Lien, Reyin, et al.
Publicado: (2016)

Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5(+) colorectal cancer
por: Feng, Haoran, et al.
Publicado: (2020)

Perivascular cell coverage of intratumoral vasculature is a predictor for bevacizumab efficacy in metastatic colorectal cancer
por: Jiang, Chang, et al.
Publicado: (2018)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
por: Mulcahy, Mary F
Publicado: (2008)

The role of pericytes on the efficacy of bevacizumab in colorectal cancer
por: BESLER, Merve, et al.
Publicado: (2022)

Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab
por: GHERMAN, ALEXANDRA, et al.
Publicado: (2017)

Clinical analysis of bevacizumab targeting therapy in treating early colorectal carcinoma after operation
por: Li, Tie-Ling, et al.
Publicado: (2017)

Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5(+) colorectal cancer
por: Feng, Haoran, et al.
Publicado: (2020)

Unraveling the Complex Interconnection between Specific Inflammatory Signaling Pathways and Mechanisms Involved in HIV-Associated Colorectal Oncogenesis
por: Damane, Botle Precious, et al.
Publicado: (2023)

Congenital cardiac liver cirrhosis with combined hepatocellular-cholangiocarcinoma—a case report
por: El Dika, Imane, et al.
Publicado: (2022)

Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors
por: Sunakawa, Yu, et al.
Publicado: (2018)

SGK1 Target Genes Involved in Heart and Blood Vessel Functions in PC12 Cells
por: Li, Yu-He, et al.
Publicado: (2023)

Perfusion imaging of colorectal liver metastases treated with bevacizumab and stereotactic body radiotherapy
por: Detsky, Jay S., et al.
Publicado: (2018)

Synergistic effects of curcumin and bevacizumab on cell signaling pathways in hepatocellular carcinoma
por: GAO, JIAN-ZHI, et al.
Publicado: (2015)

Use of Bevacizumab in Metastatic Colorectal Cancer: Report from the Mexican Opinion and Analysis Forum on Colorectal Cancer Treatment with Bevacizumab (September 2009)
por: Zinser-Sierra, Juan W., et al.
Publicado: (2012)

Platelet-Derived Growth Factor Receptor-α Subunit Targeting Suppresses Metastasis in Advanced Thyroid Cancer (In Vitro) and (In Vivo)
por: Lin, Ching-Ling, et al.
Publicado: (2021)

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
por: Stein, Alexander, et al.
Publicado: (2015)

Role of VEGFA gene polymorphisms in colorectal cancer patients who treated with bevacizumab
por: Cui, Wei, et al.
Publicado: (2017)

Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer
por: Zoratto, Federica, et al.
Publicado: (2012)

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
por: Di Bartolomeo, Maria, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2h0fq1fimjjoncm0snml9m0m4p